Cancer immunotherapy — the process of activating a patient’s own immune system to fight a tumor — is a booming field in drug development. But it faces certain hurdles. Fewer than a quarter of cancer patients benefit from leading drugs in the class known as “checkpoint inhibitors.” And personalized cellular therapies are costly and complicated to create and deliver.

To help solve those challenges, scientists at Harvard have developed an implantable device that would pull immune cells into the implant, train them to recognize pieces of the patient’s tumor, and then release these cells — with the end goal of creating a sustained attack against the cancer. And last week the researchers announced they have struck a licensing agreement with Novartis to use their approach to make an implantable cancer vaccine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This is something that I am first reading about, and I am very interested in more information regarding this new technique for cancer treatments that might effectively be beneficial, more than IV Immunotherapy protocols. I hope that we have an opportunity to continue reading about this topic specifically, in the STAT newsletters whenever there are other significant issues with this protocol.
    Thank you for your sending this type of information to the readers of STAT.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy